These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34878687)

  • 21. Diagnostic Value of Conventional Polymerase Chain Reaction for Detecting BRAF V595E Mutation in Liquid and Tissue Specimens of Canine Urothelial and Prostate Carcinomas.
    Kuo CC; Yang SY; Liu RM; Lin YH; Liu CC; Huang WH; Lee JJ; Liao AT
    Animals (Basel); 2024 Aug; 14(17):. PubMed ID: 39272320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomy.
    Bradbury ML; Mullin CM; Gillian SD; Weisse C; Bergman PJ; Morges MA; May LR; Vail DM; Clifford CA
    Can Vet J; 2021 Feb; 62(2):133-140. PubMed ID: 33542551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.
    Marvel SJ; Séguin B; Dailey DD; Thamm DH
    Vet Comp Oncol; 2017 Dec; 15(4):1417-1427. PubMed ID: 28217972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Artificial Intelligence to Predict the BRAF V595E Mutation in Canine Urinary Bladder Urothelial Carcinomas.
    Küchler L; Posthaus C; Jäger K; Guscetti F; van der Weyden L; von Bomhard W; Schmidt JM; Farra D; Aupperle-Lellbach H; Kehl A; Rottenberg S; de Brot S
    Animals (Basel); 2023 Jul; 13(15):. PubMed ID: 37570213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
    Upton ML; Tangner CH; Payton ME
    J Am Vet Med Assoc; 2006 Feb; 228(4):549-52. PubMed ID: 16478428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hotspot Exon 15 Mutations in BRAF Are Uncommon in Feline Tumours.
    Kuroki K; Hoang CT; Rogic AM; Rindt H; Simenson A; Noall LG; Bryan JN; Johnson GC; Chu S
    Vet Comp Oncol; 2024 Sep; 22(3):452-456. PubMed ID: 39015955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Fibromyxoid Stromal Response is Associated with Muscle Invasion in Canine Urothelial Carcinoma.
    de Brot S; Grau-Roma L; Stirling-Stainsby C; Dettwiler M; Guscetti F; Meier D; Scase T; Robinson BD; Gardner D; Mongan NP
    J Comp Pathol; 2019 May; 169():35-46. PubMed ID: 31159949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meloxicam in Combination with Mitoxantrone or Vinblastine as First-Line Treatment for Non-Resectable Urothelial Cell Carcinoma in Dogs.
    Ciriano Cerdà E; Zajc AL; Finotello R; Macdonald K; Lyseight F; Van Den Steen N; Sanchez Gonzalez K; Marrington M; Grant J
    Vet Sci; 2023 Aug; 10(8):. PubMed ID: 37624316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).
    Kim JH; Ahn DH; Moon JS; Han HJ; Bae K; Yoon KA
    Vet Q; 2021 Dec; 41(1):153-162. PubMed ID: 33764261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphatic invasion is a significant indicator of poor patient outcome in canine bladder urothelial carcinoma.
    Govoni VM; Pigoli C; Sueiro FAR; Zuliani F; da Silva TO; Quitzan JG; Laufer-Amorim R; Grieco V; Fonseca-Alves CE
    Open Vet J; 2021; 11(4):535-543. PubMed ID: 35070848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic challenge in veterinary pathology: Detection of
    Chambers JK; Takahashi N; Kato S; Hashimoto Y; Goto-Koshino Y; Uchida K
    Vet Pathol; 2024 May; 61(3):335-338. PubMed ID: 38088189
    [No Abstract]   [Full Text] [Related]  

  • 32. Survival analysis in dogs with urinary transitional cell carcinoma that underwent whole-body computed tomography at diagnosis.
    Iwasaki R; Shimosato Y; Yoshikawa R; Goto S; Yoshida K; Murakami M; Kawabe M; Sakai H; Mori T
    Vet Comp Oncol; 2019 Sep; 17(3):385-393. PubMed ID: 31012230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of the current standing of microRNA expression in canine urothelial carcinoma.
    Varvil MS; Dos Santos AP
    Am J Vet Res; 2024 Oct; 85(10):. PubMed ID: 39047791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
    Allstadt SD; Rodriguez CO; Boostrom B; Rebhun RB; Skorupski KA
    J Vet Intern Med; 2015 Jan; 29(1):261-7. PubMed ID: 25619518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue S100/calgranulin expression and blood neutrophil-to-lymphocyte ratio (NLR) in dogs with lower urinary tract urothelial carcinoma.
    Weinekötter J; Gurtner C; Protschka M; von Bomhard W; Böttcher D; Schlinke A; Alber G; Rösch S; Steiner JM; Seeger J; Oechtering GU; Heilmann RM
    BMC Vet Res; 2022 Nov; 18(1):412. PubMed ID: 36411489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
    Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
    Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reason for euthanasia in dogs with urothelial carcinoma treated with chemotherapy or radiation therapy or both: A retrospective observational study.
    McKenna C; Poirier VJ; Oblak ML; Nykamp S; Mutsaers AJ
    J Vet Intern Med; 2024; 38(2):1127-1134. PubMed ID: 38317542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder.
    Tsuboi M; Sakai K; Maeda S; Chambers JK; Yonezawa T; Matsuki N; Uchida K; Nakayama H
    Vet Pathol; 2019 May; 56(3):369-376. PubMed ID: 30612533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly recurrent BRAF p.V595E mutation in canine papillary oral squamous cell carcinoma.
    Peralta S; Webb SM; Katt WP; Grenier JK; Duhamel GE
    Vet Comp Oncol; 2023 Mar; 21(1):138-144. PubMed ID: 36451536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma.
    Setyo LC; Donahoe SL; Shearer PL; Wang P; Krockenberger MB
    J Vet Diagn Invest; 2023 Mar; 35(2):109-115. PubMed ID: 36648148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.